{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:02:19Z","timestamp":1776139339920,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":149,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2024.100824","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T07:46:45Z","timestamp":1717141605000},"page":"100824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status"],"prefix":"10.1016","volume":"40","author":[{"given":"Ivo","family":"Abraham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0001","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/13696998.2021.2020570","article-title":"Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers","volume":"25","author":"Epstein","year":"2022","journal-title":"J. Med. Econ."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100824_bib0002","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed?","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2024.100824_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/bmjspcare-2021-003082","article-title":"Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment","author":"Scotte","year":"2021","journal-title":"BMJ Support. Palliat. Care"},{"issue":"4","key":"10.1016\/j.ctarc.2024.100824_bib0004","first-page":"228","article-title":"Management and preventive measures for febrile neutropenia,","volume":"43","author":"Lucas","year":"2018","journal-title":"P. T."},{"key":"10.1016\/j.ctarc.2024.100824_bib0005","series-title":"\"Hematopoietic Growth Factors,\u201c in NCCN Clinical Practice Guidelines in Oncology","year":"2023"},{"issue":"s1","key":"10.1016\/j.ctarc.2024.100824_bib0006","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/383050","article-title":"Management of fever in neutropenic patients with different risks of complications","volume":"39","author":"Klastersky","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"suppl_5","key":"10.1016\/j.ctarc.2024.100824_bib0007","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2024.100824_bib0008","series-title":"Filgrastim: Highlights of Prescribing Information","year":"2015"},{"issue":"3","key":"10.1016\/j.ctarc.2024.100824_bib0009","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer,","volume":"20","author":"Holmes","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2024.100824_bib0011","article-title":"Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100824_bib0012","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1007\/s10238-023-01159-1","article-title":"The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study","volume":"23","author":"Mollica","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2024.100824_bib0013","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/ijms22041551","article-title":"Treating prostate cancer by antibody\u2013drug conjugates","volume":"22","author":"Rosellini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100824_bib0014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/13543784.2022.2042252","article-title":"Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert. Opin. Investig. Drug."},{"key":"10.1016\/j.ctarc.2024.100824_bib0015","unstructured":"Food and Drug Administration. \u201cNeulasta Product Information.\u201d https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125031s198lbl.pdf (accessed 29 June 2023)."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00520-017-3841-2","article-title":"Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey","volume":"26","author":"Hauber","year":"2018","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1078155220980517","article-title":"Real-world effectiveness of the pegfilgrastim on-body injector in preventing severe neutropenia","volume":"28","author":"Maahs","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"10","key":"10.1016\/j.ctarc.2024.100824_bib0018","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.1007\/s00520-022-07226-9","article-title":"A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices","volume":"30","author":"Rifkin","year":"2022","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ctarc.2024.100824_bib0019","first-page":"363","article-title":"Formative study on the wearability and usability of a large-volume patch injector","volume":"14","author":"Lange","year":"2021","journal-title":"Med. Dev.: Evid. Res."},{"key":"10.1016\/j.ctarc.2024.100824_bib0020","unstructured":"Repatha. \u201cPushtronex\u00ae.\u201d https:\/\/www.repathahcp.com\/about-repatha\/dosing (accessed 29 June 2023)."},{"key":"10.1016\/j.ctarc.2024.100824_bib0021","unstructured":"SC Pharmaceuticals. \u201cFUROSCIX\u00ae.\u201d https:\/\/www.scpharmaceuticals.com\/products\/furoscix\/(accessed 29 June 2023)."},{"key":"10.1016\/j.ctarc.2024.100824_bib0022","unstructured":"enable injections. \u201cenFuse\u00a9.\u201d https:\/\/enableinjections.com\/enfuse-wearable-delivery\/(accessed 29 June 2023)."},{"key":"10.1016\/j.ctarc.2024.100824_bib0023","unstructured":"Amgen, \u201cAmgen Launches Neulasta\u00ae (pegfilgrastim) Onpro\u00ae NARRATIVES,\u201d ed, 2018, (accessed 11 December 2023)."},{"key":"10.1016\/j.ctarc.2024.100824_bib0024","unstructured":"Coherus BioSciences, Inc. \u201cCoherus Announces FDA Approval of UDENYCA ONBODY\u2122, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv.\u201d http:\/\/tinyurl.com\/38swdy27 (accessed 30 January 2024)."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2024.100824_bib0025","doi-asserted-by":"crossref","first-page":"e18859","DOI":"10.1200\/JCO.2018.36.15_suppl.e18859","article-title":"Effect of pegfilgrastim on-body injector (OBI) on cancer care: a real-world health system and interrupted time series analysis","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2024.100824_bib0026","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood-2018-99-114282","article-title":"Incidence of neutropenic fever at a safety net hospital in cancer chemotherapy patients receiving prophylactic pegfilgrastim manual injection compared to the on-body auto-injector","volume":"132","author":"Jindal","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2024.100824_bib0027","doi-asserted-by":"crossref","DOI":"10.1080\/13696998.2021.1916863","article-title":"Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment","author":"McBride","year":"2021","journal-title":"J. Med. Econ."},{"issue":"7","key":"10.1016\/j.ctarc.2024.100824_bib0028","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1007\/s00520-022-07025-2","article-title":"A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis","volume":"30","author":"Mahtani","year":"2022","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0029","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/13696998.2019.1658591","article-title":"Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma","volume":"23","author":"McBride","year":"2020","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100824_bib0030","article-title":"Racial differences in accepting pegfilgrastim onpro kit (on-body injector) use among cancer patients","volume":"1","author":"Saif","year":"2019","journal-title":"Clin. Oncol. (Las. Vegas)"},{"issue":"9","key":"10.1016\/j.ctarc.2024.100824_bib0031","first-page":"1230","article-title":"Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis","volume":"27","author":"McBride","year":"2021","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100824_bib0032","doi-asserted-by":"crossref","first-page":"796","DOI":"10.6004\/jadpro.2022.13.8.6","article-title":"Meta-analysis of same-day pegfilgrastim administration stratified by myelotoxic febrile neutropenia risk and tumor type","volume":"13","author":"Alrawashdh","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.ctarc.2024.100824_bib0033","article-title":"Safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for gastrointestinal malignancies","author":"Matera","year":"2021","journal-title":"Cancer Med. J."},{"issue":"26","key":"10.1016\/j.ctarc.2024.100824_bib0034","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.2217\/fon-2021-0532","article-title":"Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy","volume":"17","author":"McBride","year":"2021","journal-title":"Futur. Oncol."},{"key":"10.1016\/j.ctarc.2024.100824_bib0035","series-title":"NCCN Hematopoietic Growth Factors Short-Term Recommendations Specific to Issues with COVID-19 (SARS-CoV-2)","year":"2020"},{"issue":"2","key":"10.1016\/j.ctarc.2024.100824_bib0036","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/0018578719867659","article-title":"Retrospective analysis of clinical outcomes associated with the use of pegfilgrastim on-body injector in patients receiving chemotherapy requiring granulocyte colony-stimulating factor support","volume":"56","author":"Patel","year":"2021","journal-title":"Hosp. Pharm."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0037","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/acm2.13156","article-title":"Initial testing of pegfilgrastim (Neulasta Onpro) on-body injector in multiple radiological imaging environments","volume":"22","author":"Long","year":"2021","journal-title":"J. Appl. Clin. Med. Phys."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2024.100824_bib0038","doi-asserted-by":"crossref","first-page":"e18273","DOI":"10.1200\/JCO.2017.35.15_suppl.e18273","article-title":"Retrospective review of pegfilgrastim on-body injector delivery rates in a large health system","volume":"35","author":"Stuessy","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0039","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1186\/s12885-019-6010-9","article-title":"Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2024.100824_bib0040","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/03007995.2018.1558851","article-title":"Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment","volume":"35","author":"Weycker","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100824_bib0041","article-title":"Neulasta onpro: a coup de gr\u00e2ce?","volume":"29","author":"Jensen","year":"2023","journal-title":"Am. J. Manage Care"},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0042","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1188\/17.CJON.121-122","article-title":"On-body injector: an administration device for pegfilgrastim","volume":"21","author":"Mahler","year":"2017","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.ctarc.2024.100824_bib0043","unstructured":"Amgen. \u201cNeulasta OnPro.\u201d https:\/\/www.neulastahcp.com\/reliability-innovation (accessed 11 December 2023)."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0044","doi-asserted-by":"crossref","first-page":"21","DOI":"10.6004\/jnccn.2022.7073","article-title":"A Survey of the national comprehensive cancer network on approaches toward addressing patients\u2019 transportation insecurity","volume":"21","author":"Chaiyachati","year":"2023","journal-title":"J. Natl. Compreh. Cancer Netw."},{"issue":"12","key":"10.1016\/j.ctarc.2024.100824_bib0045","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/jnci\/djac134","article-title":"Addressing transportation insecurity among patients with cancer","volume":"114","author":"Graboyes","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2024.100824_bib0046","unstructured":"L. Goldfarb. \u201cOn the rise: wearable injector systems.\u201d Med. Des. Brief.. https:\/\/www.medicaldesignbriefs.com\/component\/content\/article\/mdb\/pub\/features\/articles\/39771 (accessed 14 September 2023)."},{"key":"10.1016\/j.ctarc.2024.100824_bib0047","unstructured":"OmniPod. \u201cPODPALS\u2122 - OMNIPOD\u00ae ADHESIVE OVERLAYS.\u201d https:\/\/omnipod.diabetesexpress.ca\/products\/podpals-omnipod-adhesive-overlays (accessed 11 December 2023)."},{"issue":"2","key":"10.1016\/j.ctarc.2024.100824_bib0048","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3122\/jabfm.2022.02.210256","article-title":"Content analysis of transportation screening questions in social risk assessment tools: are we capturing transportation insecurity?","volume":"35","author":"Razon","year":"2022","journal-title":"J. Am. Board Fam. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2024.100824_bib0049","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/OP.20.01071","article-title":"Maximizing home time for persons with cancer","volume":"17","author":"Banerjee","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ctarc.2024.100824_bib0050","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/GO.20.00351","article-title":"Impact of the COVID-19 pandemic on cancer care: a global collaborative study","volume":"6","author":"Jazieh","year":"2020","journal-title":"JCO Glob. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0051","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/13696998.2021.1916863","article-title":"Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment","volume":"24","author":"McBride","year":"2021","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0052","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12939-023-01860-3","article-title":"Barriers to cancer treatment and care for people experiencing structural vulnerability: a secondary analysis of ethnographic data","volume":"22","author":"Bourgeois","year":"2023","journal-title":"Int. J. Equity. Health"},{"key":"10.1016\/j.ctarc.2024.100824_bib0053","unstructured":"J. Baker. \u201cEducating Patients On Self-Administered Drug Injections.\u201d Pharmaceutical Commerce. https:\/\/www.pharmaceuticalcommerce.com\/view\/educating-patients-on-self-administered-drug-injections (accessed 29 June 2023)."},{"key":"10.1016\/j.ctarc.2024.100824_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100824_bib0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/14712598.2023.2247916","article-title":"Preparing for the third decade of biosimilars","volume":"23","author":"Abraham","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100824_bib0056","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/13696998.2018.1452747","volume":"21","author":"Bensink","year":"2018","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.ctarc.2024.100824_bib0057","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/13696998.2018.1452749","article-title":"Reply: cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia","volume":"21","author":"McBride","year":"2018","journal-title":"J. Med. Econ."},{"issue":"8","key":"10.1016\/j.ctarc.2024.100824_bib0058","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/13696998.2020.1760284","article-title":"Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim","volume":"23","author":"McBride","year":"2020","journal-title":"J. Med. Econ."},{"issue":"12","key":"10.1016\/j.ctarc.2024.100824_bib0059","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/13696998.2020.1833339","article-title":"Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv","volume":"23","author":"MacDonald","year":"2020","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.ctarc.2024.100824_bib0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/fon-2021-0979","article-title":"Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients","volume":"18","author":"McBride","year":"2022","journal-title":"Futur. Oncol."},{"issue":"33","key":"10.1016\/j.ctarc.2024.100824_bib0061","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.2217\/fon-2021-0718","article-title":"Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer","volume":"17","author":"MacDonald","year":"2021","journal-title":"Futur. Oncol."},{"key":"10.1016\/j.ctarc.2024.100824_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106591","article-title":"Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma","volume":"106","author":"McBride","year":"2021","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2024.100824_bib0063","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s12913-023-09454-z","article-title":"Health professionals\u2019 preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia","volume":"23","author":"Larrarte-Gonz\u00e1lez","year":"2023","journal-title":"BMC. Health Serv. Res."},{"key":"10.1016\/j.ctarc.2024.100824_bib0064","unstructured":"American Cancer Society. \u201cOut-of-Pocket Spending Limits Are Crucial for Cancer Patients & Survivors.\u201d Pubic Policy Resour.. https:\/\/www.fightcancer.org\/policy-resources\/out-pocket-spending-limits-are-crucial-cancer-patients-survivors (accessed 14 September 2023)."},{"key":"10.1016\/j.ctarc.2024.100824_bib0065","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jval.2020.04.1670","article-title":"PCN192 Incidence of febrile neutropenia and enviromental factors observed with optimal receipt of pegfilgrastim via on-body injector or pre-filled syringe after chemotherapy","volume":"23","author":"Bonafede","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.ctarc.2024.100824_bib0066","series-title":"Emerging Trends in Wearable Drug Delivery","first-page":"17","author":"Bedford","year":"2020"},{"issue":"10","key":"10.1016\/j.ctarc.2024.100824_bib0067","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/13696998.2017.1358173","article-title":"Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia","volume":"20","author":"McBride","year":"2017","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ctarc.2024.100824_bib0068","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jval.2020.04.1670","article-title":"PCN192. Incidence of febrile neutropenia and environmental factors observed with optimal receipt of pegfilgrastim on-body injectors or pre-filled syringe after chemotherapy","volume":"23","author":"Bonafede","year":"2020","journal-title":"Value in Health"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294224000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T07:26:47Z","timestamp":1725089207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294224000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":68,"alternative-id":["S2468294224000364"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100824","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2024.100824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100824"}}